Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchNitazoxanideNitazoxanide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Romark, NCT04359680, NCT04359680
Jun 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Progression 43% Improvement Relative Risk Time to perform usual act.. 50% Time to usual health 32% Acute respiratory illness t.. 28% Case 3% Nitazoxanide  Romark et al.  Prophylaxis  DB RCT Is prophylaxis with nitazoxanide beneficial for COVID-19? Double-blind RCT 1,407 patients in the USA Lower progression with nitazoxanide (p=0.021) c19early.org Romark, NCT04359680, June 2024 Favorsnitazoxanide Favorscontrol 0 0.5 1 1.5 2+
RCT 1,407 healthcare workers and others at high risk of SARS-CoV-2 exposure, showing no difference in COVID-19 cases (13 in each group). There was lower symptom severity for nitazoxanide and a trend towards shorter illness duration. There is no publication, results are only available on clinicaltrials.gov, posted 3 years after completion (FDA pre-notice of noncompliance1).
risk of progression, 43.5% lower, RR 0.57, p = 0.02, treatment mean 1.3 (±0.95) n=13, control mean 2.3 (±1.11) n=13.
time to perform usual activities, 50.3% lower, RR 0.50, p = 0.10, treatment mean 8.2 (±11.73) n=13, control mean 16.5 (±12.72) n=13.
time to usual health, 32.3% lower, RR 0.68, p = 0.32, treatment mean 13.2 (±16.88) n=13, control mean 19.5 (±14.58) n=13.
acute respiratory illness time, 27.5% lower, RR 0.72, p = 0.49, treatment mean 10.0 (±15.52) n=13, control mean 13.8 (±12.05) n=13.
risk of case, 2.5% lower, RR 0.97, p = 1.00, treatment 13 of 629 (2.1%), control 13 of 613 (2.1%), NNT 1854.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Romark et al., 26 Jun 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04359680 (history).
This PaperNitazoxanideAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit